Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Vicore Pharma Holding AB ( (SE:VICO) ) is now available.
Vicore Pharma Holding AB has announced the formation of its Nomination Committee for the 2026 Annual General Meeting, comprising representatives from its three largest shareholders and the company’s chairman. This committee is tasked with preparing proposals for board elections, remuneration, and auditor appointments for the AGM scheduled for May 6, 2026. The announcement underscores Vicore’s commitment to structured governance and stakeholder engagement as it continues to advance its pharmaceutical innovations.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), aimed at treating respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). The company’s lead product, buloxibutid, is under investigation in a Phase 2b trial and has received Orphan Drug and Fast Track designation from the FDA. Vicore is publicly listed on the Nasdaq Stockholm exchange.
YTD Price Performance: 34.20%
Average Trading Volume: 775,918
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.66B
See more insights into VICO stock on TipRanks’ Stock Analysis page.